BioNTech to cut fifth of workforce as it winds down Covid vaccine production
German biotech is shifting towards cancer treatments
Related reading
Co-founders behind pioneering Covid vaccine to step down from BioNTech
Uğur Şahin and Özlem Türeci are leaving German group to launch their own mRNA venture
BioNTech settles Covid-19 patent dispute with CureVac
UK’s GSK will receive $370mn and 1% of sales of some vaccines as part of the deal
Merck nears $6bn biotech deal to boost cancer drug pipeline
Terns Pharma stock has jumped since promising clinical data on its bone and blood cancer treatment last year
How GSK is rebuilding its cancer business
A decade after exiting oncology, the UK pharma group is betting that R&D and acquisitions will help it hit sales of £40bn
Merck transforms itself through dealmaking as clock ticks on top-selling drug
Acquisitions fuel pharma group’s evolution as it prepares to lose patent protection on cancer drug Keytruda
Amgen swoops on UK cancer biotech in deal worth up to $840mn
Dark Blue Therapeutics was spun out of an Oxford university incubator in 2022